Latest Content

Golidocitinib Plus PD-1 Antibodies Being Explored in Lung Cancer Subset

March 20th 2025, 4:08pm

By Alex Biese

Article

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.

Development of EO-3021 Discontinued for Gastric and GEJ Cancers

March 20th 2025, 3:02pm

By Spencer Feldman

Article

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows insufficient efficacy.

Kadcyla Continues to Show Benefits in Early HER2+ Breast Cancer

March 20th 2025, 1:00pm

By Dr. Charles E. Geyer

Video

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

Gene Expression Testing and Targeted Therapies in Breast Cancer Care

March 19th 2025, 9:00pm

By Spencer Feldman

Article

Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.

How Antibody-Drug Conjugates Have Impacted HER2-Positive Breast Cancer Treatment

March 19th 2025, 8:00pm

By Dr. Charles E. Geyer

Video

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

FDA Approves Keytruda in HER2+ Gastric, Gastroesophageal Junction Cancer

March 19th 2025, 6:29pm

By Spencer Feldman

Article

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Painting an Accurate Portrait of Breast Cancer Survivorship

March 19th 2025, 5:00pm

By Bonnie Annis

Article

As a breast cancer survivor, I feel it is incumbent upon me to give an accurate picture of cancer to others, particularly newly diagnosed patients.

Fruzaqla Plus Sintilimab May Slow Renal Cell Carcinoma Progression

March 19th 2025, 4:00pm

By Alex Biese

Article

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

FDA Grants Compassionate Use Treatment to Namodenoson in Pancreatic Cancer

March 19th 2025, 3:00pm

By Ryan Scott

Article

The FDA has granted approval to an act of compassionate use treatment with the anti-cancer drug Namodenoson for a patient with pancreatic cancer.

Disparities in Breast Cancer Care, Genomic Insights and Early Detection

March 19th 2025, 1:00pm

By Ryan Scott

Article

Dr. Regina Hampton highlighted unmet needs in black women with breast cancer and details how genomic information can drive effective treatment options.

Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma

March 18th 2025, 9:00pm

By Alex Biese

Article

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.

Understanding Genetic and Genomic Testing in Breast Cancer

March 18th 2025, 8:01pm

By Spencer Feldman

Article

Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.

Investigating Quality of Life and Treatment Adherence in Kidney Cancer

March 18th 2025, 7:00pm

By Dr. Emre Yekedüz

Video

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.

Life Lessons I Learned After My Colon Cancer Diagnosis

March 18th 2025, 5:00pm

By Carla Deschamps

Article

After being diagnosed with colon cancer, I learned the life-changing lessons of self-love, stepping out of my comfort zone and embracing positive thinking.

Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia

March 18th 2025, 4:00pm

By Spencer Feldman

Article

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.